Losmapimod enters Phase III for Acute Coronary Syndrome - GSK
GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with Acute Coronary Syndrome, this being LATITUDE-TIMI 60, to evaluate the effects of losmapimod in patients presenting with Acute Coronary Syndrome. The global, phase III study will assess whether losmapimod can reduce the risk of a subsequent cardiac event when administered orally twice a day for a period of three months immediately after presentation with an Acute Coronary Syndrome.
Acute Coronary Syndrome is a term used to describe situations or events, including heart attack, where there is an abrupt reduction of blood flow to the heart through the coronary arteries. Presentation by a patient with Acute Coronary Syndrome is a manifestation of coronary heart disease.
Losmapimod is an inhibitor of p38 mitogen activated protein (MAP) kinase, an enzyme understood to play a central role in the acute inflammation that occurs during a heart attack.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.